Johan Hansson

Publications
CV
Public outreach and news

Articles

Article: CANCERS. 2022;14(4):1040
Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
Naeser Y; Helgadottir H; Hansson J; Ingvar C; Elander NO; Flygare P; Nilsson C; Jakobsson F; Valachis A; Papantoniou D; Nordin Danfors A; Johansson H; Sundin A; Brandberg Y; Ullenhag GJ
Article: ACTA ONCOLOGICA. 2022;61(1):14-21
A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma
Falkenius J; Keskitalo J; Kanter L; Johansson H; Hoiom V; Hansson J; Brage SE
Article: SCIENTIFIC REPORTS. 2021;11(1):11023
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jonsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grander D; Brage SE; Johnsson P
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021;9(5):e002171
Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+monocytes in the blood
Pour SR; de Coana YP; Martinez Demorentin X; Melief J; Thimma M; Wolodarski M; Gomez-Cabrero D; Hansson J; Kiessling R; Tegner J
Article: BMC PUBLIC HEALTH. 2021;21(1):692
Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families
Lacson JCA; Zamani SA; Froes Jr LAR; Mitra N; Qian L; Doyle SH; Azizi E; Balestrini C; Bishop DT; Bruno W; Carlos-Ortega B; Cuellar F; Cust AE; Elder DE; Gerdes A-M; Ghiorzo P; Grazziotin TC; Gruis NA; Hansson J; Hocevar M; Hoiom V; Holland EA; Ingvar C; Landman G; Larre-Borges A; Mann GJ; Molgo M; Moredo LF; Olsson H; Out-Luiting JJ; Peric B; Pjanova D; Puig S; Salas-Alanis J; Schmid H; Wadt KAW; Newton-Bishop JA; Kanetsky PA
Article: BMC CANCER. 2020;20(1):1197
TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma
Naeser Y; Helgadottir H; Brandberg Y; Hansson J; Bagge RO; Elander NO; Ingvar C; Isaksson K; Flygare P; Nilsson C; Jakobsson F; del Val Munoz O; Valachis A; Jansson M; Sparring C; Ohlsson L; Dyrke U; Papantoniou D; Sundin A; Ullenhag GJ
Article: CELL DEATH AND DISEASE. 2020;11(10):882
Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
Das I; Chen H; Maddalo G; Tuominen R; Rebecca VW; Herlyn M; Hansson J; Davies MA; Brage SE
Article: MELANOMA RESEARCH. 2020;30(5):443-454
Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
Vidarsdottir L; Fernandes RV; Zachariadis V; Das I; Edsbacker E; Sigvaldadottir I; Azimi A; Hoiom V; Hansson J; Grander D; Egyhazi Brage S; Pokrovskaja Tamm K
Article: ONCOIMMUNOLOGY. 2020;9(1):1786888
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
de Coana YP; Wolodarski M; Avila IVDH; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
Lovgren T; Wolodarski M; Wickstrom S; Edback U; Wallin M; Martell E; Markland K; Blomberg P; Nystrom M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Article: CELL DEATH AND DIFFERENTIATION. 2020;27(7):2081-2098
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
Das I; Gad H; Braeutigam L; Pudelko L; Tuominen R; Hoiom V; Almlof I; Rajagopal V; Hansson J; Helleday T; Brage SE; Berglund UW
Article: NATURE GENETICS. 2020;52(5):494-504
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
Landi MT; Bishop DT; MacGregor S; Machiela MJ; Stratigos AJ; Ghiorzo P; Brossard M; Calista D; Choi J; Fargnoli MC; Zhang T; Rodolfo M; Trower AJ; Menin C; Martinez J; Hadjisavvas A; Song L; Stefanaki I; Scolyer R; Yang R; Goldstein AM; Potrony M; Kypreou KP; Pastorino L; Queirolo P; Pellegrini C; Cattaneo L; Zawistowski M; Gimenez-Xavier P; Rodriguez A; Elefanti L; Manoukian S; Rivoltini L; Smith BH; Loizidou MA; Del Regno L; Massi D; Mandala M; Khosrotehrani K; Akslen LA; Amos CI; Andresen PA; Avril M-F; Azizi E; Soyer HP; Bataille V; Dalmasso B; Bowdler LM; Burdon KP; Chen WV; Codd V; Craig JE; Debniak T; Falchi M; Fang S; Friedman E; Simi S; Galan P; Garcia-Casado Z; Gillanders EM; Gordon S; Green A; Gruis NA; Hansson J; Harland M; Harris J; Helsing P; Henders A; Hocevar M; Hoiom V; Hunter D; Ingvar C; Kumar R; Lang J; Lathrop GM; Lee JE; Li X; Lubinski J; Mackie RM; Malt M; Malvehy J; McAloney K; Mohamdi H; Molven A; Moses EK; Neale RE; Novakovic S; Nyholt DR; Olsson H; Orr N; Fritsche LG; Anton Puig-Butille J; Qureshi AA; Radford-Smith GL; Randerson-Moor J; Requena C; Rowe C; Samani NJ; Sanna M; Schadendorf D; Schulze H-J; Simms LA; Smithers M; Song F; Swerdlow AJ; van der Stoep N; Kukutsch NA; Visconti A; Wallace L; Ward SV; Wheeler L; Sturm RA; Hutchinson A; Jones K; Malasky M; Vogt A; Zhou W; Pooley KA; Elder DE; Han J; Hicks B; Hayward NK; Kanetsky PA; Brummett C; Montgomery GW; Olsen CM; Hayward C; Dunning AM; Martin NG; Evangelou E; Mann GJ; Long G; Pharoah PDP; Easton DF; Barrett JH; Cust AE; Abecasis G; Duffy DL; Whiteman DC; Gogas H; De Nicolo A; Tucker MA; Newton-Bishop JA; Peris K; Chanock SJ; Demenais F; Brown KM; Puig S; Nagore E; Shi J; Iles MM; Law MH
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2020;69(4):513-522
High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma
Melief J; de Coana YP; Maas R; Fennemann F-L; Wolodarski M; Hansson J; Kiessling R
Article: ACTA NEUROPATHOLOGICA. 2020;139(2):347-364
Overlapping genetic architecture between Parkinson disease and melanoma
Dube U; Ibanez L; Budde JP; Benitez BA; Davis AA; Harari O; Iles MM; Law MH; Brown KM; Agee M; Alipanahi B; Auton A; Bell RK; Bryc K; Elson SL; Fontanillas P; Furlotte NA; Hinds DA; Huber KE; Kleinman A; Litterman NK; McCreight JC; McIntyre MH; Mountain JL; Noblin ES; Northover CAM; Pitts SJ; Sathirapongsasuti JF; Sazonova OV; Shelton JF; Shringarpure S; Tian C; Tung JY; Vacic V; Wilson CH; Law MH; Law MH; Bishop DT; Lee JE; Brossard M; Martin NG; Moses EK; Song F; Barrett JH; Kumar R; Easton DF; Pharoah PD; Swerdlow AJ; Kypreou KP; Taylor JC; Harland M; Randerson-Moor J; Akslen LA; Andresen PA; Avril MF; Azizi E; Scarra GB; Brown KM; Debniak T; Duffy DL; Elder DE; Fang S; Friedman E; Galan P; Ghiorzo P; Gillanders EM; Goldstein AM; Gruis NA; Hansson J; Helsing P; Hocevar M; Hoiom V; Ingvar C; Kanetsky PA; Chen WV; Landi MT; Lang J; Lathrop GM; Lubinski J; Mackie RM; Mann GJ; Molven A; Montgomery GW; Novakovic S; Olsson H; Puig S; Puig-Butille JA; Wu W; Qureshi AA; Radford-Smith GL; Van der Stoep N; Van Doorn R; Whiteman DC; Craig JE; Schadendorf E; Simms LA; Burdon KP; Nyholt DR; Pooley KA; Orr N; Stratigos AJ; Cust AE; Ward SV; Hayward NK; Han J; Schulze HJ; Dunning AM; Bishop JA; Demenais F; Amos CI; MacGregor S; Iles MM; Cruchaga C
Article: FRONTIERS IN ONCOLOGY. 2020;10:51
Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma
Rad Pour S; Morikawa H; Kiani NA; Gomez-Cabrero D; Hayes A; Zheng X; Pernemalm M; Lehtio J; Mole DJ; Hansson J; Eriksson H; Tegner J
Article: CELL DEATH AND DISEASE. 2019;10(9):663
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
Das I; Wilhelm M; Hoiom V; Marquez RF; Svedman FC; Hansson J; Tuominen R; Brage SE
Article: SCIENTIFIC REPORTS. 2019;9(1):12150
Exhaustion of CD4+T-cells mediated by the Kynurenine Pathway in Melanoma
Pour SR; Morikawa H; Kiani N; Yang M; Azimi A; Shafi G; Shang M; Baumgartner R; Ketelhuth DFJ; Kamleh MA; Wheelock CE; Lundqvist A; Hansson J; Tegner J
Article: JOURNAL OF AMERICAN ACADEMY OF DERMATOLOGY. 2019;81(2):386-394
Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT
Taylor NJ; Mitra N; Qian L; Avril M-F; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes A-M; Ghiorzo P; Goldstein AM; Grazziotin TC; Gruis NA; Hansson J; Harland M; Hayward NK; Hocevar M; Hoiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Mann GJ; Nagore E; Olsson H; Palmer JM; Peric B; Pjanova D; Pritchard AL; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Yang XR; Newton-Bishop JA; Kanetsky PA
Article: THE LANCET ONCOLOGY. 2019;20(7):948-960
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Article: THE LANCET CHILD AND ADOLESCENT HEALTH. 2019;3(5):332-342
MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort
Pellegrini C; Botta F; Massi D; Martorelli C; Facchetti F; Gandini S; Maisonneuve P; Avril M-F; Demenais F; Bressac-de Paillerets B; Hoiom V; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Marrett L; Zanetti R; Dwyer T; Thomas NE; Begg CB; Berwick M; Puig S; Potrony M; Nagore E; Ghiorzo P; Menin C; Manganoni AM; Rodolfo M; Brugnara S; Passoni E; Sekulovic LK; Baldini F; Guida G; Stratigos A; Ozdemir F; Ayala F; Fernandez-de-Misa R; Quaglino P; Ribas G; Romanini A; Migliano E; Stanganelli I; Kanetsky PA; Antonietta Pizzichetta M; Garcia-Borron JC; Nan H; Landi MT; Little J; Newton-Bishop J; Sera F; Fargnoli MC; Raimondi S; Massi D; Pastorino L; Menin C; Alaibac M; Manganoni AM; Facchetti F; Rodolfo M; Ferrari A; Valeri B; Fargnoli MC; Pellegrini C; Brugnara S; Sicher M; Mangiola D; Passoni E; Nazzaro G; Baldini F; Tosti G; Gandini S; Mazzarol G; Guida G; Guida S; Giudice G; Ayala F; Quaglino P; Ribero S; Astrua C; Romanini A; Migliano E; Stanganelli I; Mazzoni L; Pizzichetta MA; Berwick M; Begg C; Orlow I; Mujumdar U; Hummer A; Busam K; Roy P; Cotignola J; Monroe Y; Armstrong B; Kricker A; Litchfield M; Tucker P; Stephens N; Gallagher R; Switzer T; Marrett L; Theis B; From L; Chowdhury N; Vanasse L; Purdue M; Northrup D; Zanetti R; Rosso S; Sacerdote C; Anton-Culver H; Leighton N; Gildea M; Gruber S; Bonner J; Jeter J; Klotz J; Wilcox H; Weiss H; Millikan R; Thomas N; Mattingly D; Player J; Tse C-K; Rebbeck T; Kanetsky P; Walker A; Panossian S; Mohrenweiser H; Setlow R; Raimondi S; Autier P; Fargnoli MC; Kanetsky PA; Landi MT; Little J; Newton-Bishop J; Sera F; Caini S; Gandini S; Maisonneuve P; Hofman A; Kayser M; Liu F; Nijsten T; Uitterlinden AG; Kumar R; Bishop T; Elliott F; Nagore E; Lazovich D; Polsky D; Hansson J; Hoiom V; Ghiorzo P; Pastorino L; Gruis NA; Bavinck JNB; Aguilera P; Badenas C; Carrera C; Gimenez-Xavier P; Tell-Marti G; Dwyer T; Blizzard L; Cochrane J; Branicki W; Debniak T; Morling N; Johansen P; Mayne S; Bale A; Cartmel B; Ferrucci L; Pfeiffer R; Palmieri G; Ribas G; Menin C; Stratigos A; Kypreou K; Bowcock A; Cornelius L; Council ML; Motokawa T; Anno S; Helsing P; Andresen PA; Guida G; Guida S; Wong TH
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2766
Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
Wickstrom SL; Loevgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
Article: EUROPEAN JOURNAL OF DERMATOLOGY. 2018;28(6):775-783
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study
Hansson J; Bartley K; Karagiannis T; Grob J-J; Kunstfeld R; Dreno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Yim YM; Dimier N; Fittipaldo A; Basset-Seguin N; Hauschild A
Article: CANCER RESEARCH. 2018;78(20):5970-5979
Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma
Thrane K; Eriksson H; Maaskola J; Hansson J; Lundeberg J
Article: MELANOMA RESEARCH. 2018;28(4):333-340
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study
Ascierto PA; Bastholt L; Ferrucci PF; Hansson J; Marquez Rodas I; Payne M; Robert C; Thomas L; Utikal JS; Wolter P; Kudlac A; Tuson H; McKendrick J
Article: MOLECULAR SYSTEMS BIOLOGY. 2018;14(3):e7858
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Azimi A; Caramuta S; Seashore-Ludlow B; Bostrom J; Robinson JL; Edfors F; Tuominen R; Kemper K; Krijgsman O; Peeper DS; Nielsen J; Hansson J; Brage SE; Altun M; Uhlen M; Maddalo G
Article: PLOS ONE. 2018;13(11):e0206942
Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2017;137(12):2606-2612
Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families
Taylor NJ; Mitra N; Goldstein AM; Tucker MA; Avil M-F; Azizi E; Bergman W; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes A-M; Ghiorzo P; Grazziotin TC; Hansson J; Harland M; Hayward NK; Hocevar M; Hoiom V; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer JM; Peric B; Pjanova D; Pritchard A; Puig S; van der Stoep N; Wadt KAW; Whitaker L; Yang XR; Bishop JAN; Gruis NA; Kanetsky PA
Article: CELLULAR ONCOLOGY (DORDRECHT). 2017;40(6):631-638
ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report
Sakil HAM; Stantic M; Wolfsberger J; Brage SE; Hansson J; Wilhelm MT
Article: EUROPEAN JOURNAL OF CANCER. 2017;86:334-348
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
Basset-Seguin N; Hauschild A; Kunstfeld R; Grob J; Dreno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
Article: JOURNAL OF AMERICAN ACADEMY OF DERMATOLOGY. 2017;77(5):893-901
Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status
Helgadottir H; Tuominen R; Olsson H; Hansson J; Hoiom V
Article: INTERNATIONAL JOURNAL OF CANCER. 2017;141(7):1345-1354
Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma
Gordon D; Hansson J; Eloranta S; Gordon M; Gillgren P; Smedby KE
Article: CELL DEATH AND DISEASE. 2017;8(8):e3029
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
Azimi A; Tuominen R; Svedman FC; Caramuta S; Pernemalm M; Stolt MF; Kanter L; Kharaziha P; Lehtio J; Johansson CH; Holom V; Hansson J; Brage SE
Article: BMC CANCER. 2017;17(1):584
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
Falkenius J; Johansson H; Tuominen R; Stolt MF; Hansson J; Brage SE
Article: ANNALS OF ONCOLOGY. 2017;28(7):1631-1639
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandala M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob J-J
Article: ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 2017;409(15):3749-3756
Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma
Vikingsson S; Dahlberg J-O; Hansson J; Hoiom V; Green H
Article: LAKARTIDNINGEN. 2017;114:ELM9
[Great advances in the systemic treatment in malignant melanoma patients].
Ullenhag G; Hansson J; Ny L
Article: LAKARTIDNINGEN. 2017;114:ELAR
[Melanoma in places other than the skin: eye and mucous membrane melanomas].
All-Eriksson C; Seregard S; Hansson J
Article: EUROPEAN JOURNAL OF CANCER. 2017;75:313-322
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
Sekulovic LK; Peris K; Hauschild A; Stratigos A; Grob J-J; Nathan P; Dummer R; Forsea A-M; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
Article: ONCOTARGET. 2017;8(13):21539-21553
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
de Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nystrom M; Edback U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;139(12):2722-2729
Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence
Rockberg J; Amelio JM; Taylor A; Jorgensen L; Ragnhammar P; Hansson J
Article: HUMAN GENETICS. 2016;135(11):1241-1249
Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations
Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Hoiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2016;108(11):djw135
Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases
Helgadottir H; Hoiom V; Tuominen R; Nielsen K; Jonsson G; Olsson H; Hansson J
Article: BIOMEDICAL CHROMATOGRAPHY. 2016;30(8):1234-1239
Novel rapid liquid chromatography tandem masspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state
Vikingsson S; Stromqvist M; Svedberg A; Hansson J; Hoiom V; Green H
Article: MELANOMA RESEARCH. 2016;26(4):367-376
Prognostic and predictive value of YKL-40 in stage IIB-III melanoma
Krogh M; Christensen I; Bouwhuis M; Johansen JS; Norgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AMM; Bastholt L
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;139(3):543-553
Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden
Simberg-Danell C; Lyth J; Mansson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
Article: GENES CHROMOSOMES AND CANCER. 2016;55(7):601-611
The Role of Germline Alterations in the DNA Damage Response Genes BRIP1 and BRCA2 in Melanoma Susceptibility
Tuominen R; Engstrom PG; Helgadottir H; Eriksson H; Unneberg P; Kjellqvist S; Yang M; Linden D; Edsgard D; Hansson J; Hoiom V
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;137(9):2220-2226
CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies
Helgadottir H; Hoiom V; Tuominen R; Jonsson G; Mansson-Brahme E; Olsson H; Hansson J
Article: NATURE GENETICS. 2015;47(9):987-995
Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma
Law MH; Bishop DT; Lee JE; Brossard M; Martin NG; Moses EK; Song F; Barrett JH; Kumar R; Easton DF; Pharoah PDP; Swerdlow AJ; Kypreou KP; Taylor JC; Harland M; Randerson-Moor J; Akslen LA; Andresen PA; Avril M-F; Azizi E; Scarra GB; Brown KM; Debniak T; Duffy DL; Elder DE; Fang S; Friedman E; Galan P; Ghiorzo P; Gillanders EM; Goldstein AM; Gruis NA; Hansson J; Helsing P; Hocevar M; Hoeiom V; Ingvar C; Kanetsky PA; Chen WV; Landi MT; Lang J; Lathrop GM; Lubinski J; Mackie RM; Mann GJ; Molven A; Montgomery GW; Novakovic S; Olsson H; Puig S; Puig-Butille JA; Qureshi AA; Radford-Smith GL; van der Stoep N; van Doorn R; Whiteman DC; Craig JE; Schadendorf D; Simms LA; Burdon KP; Nyholt DR; Pooley KA; Orr N; Stratigos AJ; Cust AE; Ward SV; Hayward NK; Han J; Schulze H-J; Dunning AM; Bishop JAN; Demenais F; Amos CI; MacGregor S; Iles MM
Article: MELANOMA RESEARCH. 2015;25(4):348-356
Time trends in incidence of cutaneous melanoma by detailed anatomical location and patterns of ultraviolet radiation exposure: a retrospective population-based study
Gordon D; Gillgren P; Eloranta S; Olsson H; Gordon M; Hansson J; Smedby KE
Article: THE LANCET. 2015;386(9992):444-451
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob J-J; Chiarion-Sileni V; Lebbe C; Mandala M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Swann S; Legos JJ; Jin F; Mookerjee B; Flaherty K
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;136(12):2844-2853
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma
Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Johansson CH; Linden D; Johansson H; Stolt MF; Walker C; Snowden H; Newton-Bishop J; Hansson J; Brage SE
Article: ONCOTARGET. 2015;6(16):14139-14152
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer
Lazar V; Rubin E; Depil S; Pawitan Y; Martini J-F; Gomez-Navarro J; Yver A; Kan Z; Dry JR; Kehren J; Validire P; Rodon J; Vielh P; Ducreux M; Galbraith S; Lehnert M; Onn A; Berger R; Pierotti MA; Porgador A; Pramesh CS; Ye D-W; Carvalho AL; Batist G; Le Chevalier T; Morice P; Besse B; Vassal G; Mortlock A; Hansson J; Berindan-Neagoe I; Dann R; Haspel J; Irimie A; Laderman S; Nechushtan H; Al Omari AS; Haywood T; Bresson C; Soo KC; Osman I; Mata H; Lee JJ; Jhaveri K; Meurice G; Palmer G; Lacroix L; Koscielny S; Eterovic KA; Blay J-Y; Buller R; Eggermont A; Schilsky RL; Mendelsohn J; Soria J-C; Rothenberg M; Scoazec J-Y; Hong WK; Kurzrock R
Article: JAMA SURGERY. 2015;150(6):512-518
Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer
Del Chiaro M; Verbeke CS; Kartalis N; Mucelli RP; Gustafsson P; Hansson J; Haas SL; Segersvard R; Andren-Sandberg A; Lohr J-M
Article: MELANOMA RESEARCH. 2015;25(3):185-188
TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases
Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
Article: THE LANCET ONCOLOGY. 2015;16(6):729-736
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
Basset-Seguin N; Hauschild A; Grob J-J; Kunstfeld R; Dreno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2015;64(6):769-776
Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
Prasmickaite L; Berge G; Bettum IJ; Aamdal S; Hansson J; Bastholt L; Oijordsbakken M; Boye K; Maelandsmo GM
Article: CANCER RESEARCH. 2015;75(7):1187-1190
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy
Schwaederle M; Lazar V; Validire P; Hansson J; Lacroix L; Soria J-C; Pawitan Y; Kurzrock R
Article: JAMA DERMATOLOGY. 2015;151(4):410-416
BRAF^V600E Protein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases
Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;136(6):1351-1360
Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions
Barrett JH; Taylor JC; Bright C; Harland M; Dunning AM; Akslen LA; Andresen PA; Avril M-F; Azizi E; Scarra GB; Brossard M; Brown KM; Debniak T; Elder DE; Friedman E; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Helsing P; Hocevar M; Hoiom V; Ingvar C; Landi MT; Lang J; Lathrop GM; Lubinski J; Mackie RM; Molven A; Novakovic S; Olsson H; Puig S; Anton Puig-Butille J; van der Stoep N; van Doorn R; van Workum W; Goldstein AM; Kanetsky PA; Pharoah PDP; Demenais F; Hayward NK; Newton Bishop JA; Bishop DT; Iles MM
Article: BRITISH JOURNAL OF DERMATOLOGY. 2015;172(3):700-706
Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men
Lyth J; Eriksson H; Hansson J; Ingvar C; Jansson M; Lapins J; Mansson-Brahme E; Naredi P; Stierner U; Ullenhag G; Carstensen J; Lindholm C
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;136(3):618-631
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: A pooled-analysis from the M-SKIP project
Pasquali E; Garcia-Borron JC; Fargnoli MC; Gandini S; Maisonneuve P; Bagnardi V; Specchia C; Liu F; Kayser M; Nijsten T; Nagore E; Kumar R; Hansson J; Kanetsky PA; Ghiorzo P; Debniak T; Branicki W; Gruis NA; Han J; Dwyer T; Blizzard L; Landi MT; Palmieri G; Ribas G; Stratigos A; Council ML; Autier P; Little J; Newton-Bishop J; Sera F; Raimondi S
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2015;64(2):173-180
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels
Vihinen P; Tervahartiala T; Sorsa T; Hansson J; Bastholt L; Aamdal S; Stierner U; Pyrhonen S; Syrjanen K; Lundin J; Hernberg M
Article: BRITISH JOURNAL OF DERMATOLOGY. 2015;172(1):175-186
Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study
Eriksson H; Frohm-Nilsson M; Jaras J; Kanter-Lewensohn L; Kjellman P; Mansson-Brahme E; Vassilaki I; Hansson J
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(20):1877-1888
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Sileni VC; Lebbe C; Mandala M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin A-M; Le N; Patel K; Flaherty K
Article: INTERNATIONAL JOURNAL OF CANCER. 2014;135(7):1625-1633
Inherited variation in the PARP1 gene and survival from melanoma
Davies JR; Jewell R; Affleck P; Anic GM; Randerson-Moor J; Ozola A; Egan KM; Elliott F; Garcia-Casado Z; Hansson J; Harland M; Hoiom V; Jian G; Jonsson G; Kumar R; Nagore E; Wendt J; Olsson H; Park JY; Patel P; Pjanova D; Puig S; Schadendorf D; Rachakonda PS; Snowden H; Stratigos AJ; Bafaloukos D; Ogbah Z; Sucker A; Van den Oord JJ; Van Doorn R; Walker C; Okamoto I; Wolter P; Barrett JH; Bishop DT; Newton-Bishop J
Article: ANNALS OF SURGICAL ONCOLOGY. 2014;21(11):3386-3394
Sentinel Node Location in Trunk and Extremity Melanomas: Uncommon or Multiple Lymph Drainage Does Not Affect Survival
Gordon D; Smedby KE; Schultz I; Olsson H; Ingvar C; Hansson J; Gillgren P
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2014;106(10):dju267
The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length
Iles MM; Bishop DT; Taylor JC; Hayward NK; Brossard M; Cust AE; Dunning AM; Lee JE; Moses EK; Akslen LA; Andresen PA; Avril M-F; Azizi E; Scarra GB; Brown KM; Debniak T; Elder DE; Friedman E; Ghiorzo P; Gillanders EM; Goldstein AM; Gruis NA; Hansson J; Harland M; Helsing P; Hocevar M; Hoiom V; Ingvar C; Kanetsky PA; Landi MT; Lang J; Lathrop GM; Lubinski J; Mackie RM; Martin NG; Molven A; Montgomery GW; Novakovic S; Olsson H; Puig S; Anton Puig-Butille J; Radford-Smith GL; Randerson-Moor J; van der Stoep N; van Doorn R; Whiteman DC; MacGregor S; Pooley KA; Ward SV; Mann GJ; Amos CI; Pharoah PDP; Demenais F; Law MH; Bishop JAN; Barrett JH
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2014;63(10):1061-1071
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma
Poschke I; Lovgren T; Adamson L; Nystrom M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
Article: MATRIX BIOLOGY. 2014;38:69-83
Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146)
Ishikawa T; Wondimu Z; Oikawa Y; Gentilcore G; Kiessling R; Brage SE; Hansson J; Patarroyo M
Article: TRIALS. 2014;15:317
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial
Olofsson R; Ny L; Eilard MS; Rizell M; Cahlin C; Stierner U; Lonn U; Hansson J; Ljuslinder I; Lundgren L; Ullenhag G; Kiilgaard JF; Nilsson J; Lindner P
Article: JOURNAL OF MEDICAL GENETICS. 2014;51(8):545-552
High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families
Helgadottir H; Hoiom V; Jonsson G; Tuominen R; Ingvar C; Borg A; Olsson H; Hansson J
Article: JOURNAL OF AMERICAN ACADEMY OF DERMATOLOGY. 2014;71(2):245-248
Risk of cutaneous malignant melanoma in patients with celiac disease: A population-based study
Lebwohl B; Eriksson H; Hansson J; Green PHR; Ludvigsson JF
Article: BRITISH JOURNAL OF CANCER. 2014;110(10):2489-2495
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
Azimi A; Pernemalm M; Stolt MF; Hansson J; Lehtio J; Brage SE; Johansson CH
Article: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(13):1356-1364
Later Stage at Diagnosis and Worse Survival in Cutaneous Malignant Melanoma Among Men Living Alone: A Nationwide Population-Based Study From Sweden
Eriksson H; Lyth J; Mansson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Carstensen J; Hansson J
Article: CANCER GENETICS. 2014;207(3):70-74
Investigation of a putative melanoma susceptibility locus at chromosome 3q29
Tuominen R; Jonsson G; Enerback C; Appelqvist F; Olsson H; Ingvar C; Hansson J; Hoiom V
Article: PIGMENT CELL AND MELANOMA RESEARCH. 2014;27(2):234-243
An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study
Davies JR; Field S; Randerson-Moor J; Harland M; Kumar R; Anic GM; Nagore E; Hansson J; Hoeiom V; Joensson G; Gruis NA; Park JY; Guan J; Rachakonda PS; Wendt J; Pjanova D; Puig S; Schadendorf D; Okamoto I; Olsson H; Affleck P; Garcia-Casado Z; Anton Puig-Butille J; Stratigos AJ; Kodela E; Donina S; Sucker A; Hosen I; Egan KM; Barrett JH; van Doorn R; Bishop DT; Newton-Bishop J
Article: CANCER EPIDEMIOLOGY. 2014;38(1):93-99
Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study
Andersson TM-L; Eriksson H; Hansson J; Mansson-Brahme E; Dickman PW; Eloranta S; Lambe M; Lambert PC
Article: BMC MEDICAL GENOMICS. 2013;6:53
Integrated molecular portrait of non-small cell lung cancers
Lazar V; Suo C; Orear C; van den Oord J; Balogh Z; Guegan J; Job B; Meurice G; Ripoche H; Calza S; Hasmats J; Lundeberg J; Lacroix L; Vielh P; Dufour F; Lehtio J; Napieralski R; Eggermont A; Schmitt M; Cadranel J; Besse B; Girard P; Blackhall F; Validire P; Soria J-C; Dessen P; Hansson J; Pawitan Y
Article: MELANOMA RESEARCH. 2013;23(6):452-460
High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma
Falkenius J; Lundeberg J; Johansson H; Tuominen R; Frostvik-Stolt M; Hansson J; Brage SE
Article: JOURNAL OF DERMATOLOGICAL SCIENCE. 2013;72(3):284-289
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma
Zebary A; Omholt K; Vassilaki I; Hoiom V; Linden D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
Article: MELANOMA RESEARCH. 2013;23(5):360-365
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines
Johansson CH; Azimi A; Stolt MF; Shojaee S; Wiberg H; Grafstrom E; Hansson J; Brage SE
Article: CANCER IMMUNOLOGY RESEARCH. 2013;1(3):158-162
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
de Coana YP; Poschke I; Gentilcore G; Mao Y; Nystrom M; Hansson J; Masucci GV; Kiessling R
Article: BRITISH JOURNAL OF CANCER. 2013;109(3):559-564
KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
Article: ACTA ONCOLOGICA. 2013;52(6):1086-1093
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma
Brandberg Y; Johansson H; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(12):2705-2716
Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: A nationwide population-based study in Sweden
Eriksson H; Lyth J; Mansson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Wagenius G; Carstensen J; Hansson J
Article: ACTA DERMATO-VENEREOLOGICA. 2013;93(4):411-416
Interobserver Variability of Histopathological Prognostic Parameters in Cutaneous Malignant Melanoma: Impact on Patient Management
Eriksson H; Frohm-Nilsson M; Hedblad M-A; Hellborg H; Kanter-Lewensohn L; Krawiec K; Lundh Rozell B; Mansson-Brahme E; Hansson J
Article: CANCER RESEARCH. 2013;73(13):3877-3887
Melanoma-Educated CD14⁺ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Mao Y; Poschke I; Wennerberg E; de Coana YP; Brage SE; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: NATURE GENETICS. 2013;45(4):428-432
A variant in FTO shows association with melanoma risk not due to BMI
Iles MM; Law MH; Stacey SN; Han J; Fang S; Pfeiffer R; Harland M; MacGregor S; Taylor JC; Aben KK; Akslen LA; Avril M-F; Azizi E; Bakker B; Benediktsdottir KR; Bergman W; Scarra GB; Brown KM; Calista D; Chaudru V; Fargnoli MC; Cust AE; Demenais F; Waal ACD; Debniak T; Elder DE; Friedman E; Galan P; Ghiorzo P; Gillanders EM; Goldstein AM; Gruis NA; Hansson J; Helsing P; Hocevar M; Hoiom V; Hopper JL; Ingvar C; Janssen M; Jenkins MA; Kanetsky PA; Kiemeney LA; Lang J; Lathrop GM; Leachman S; Lee JE; Lubinski J; Mackie RM; Mann GJ; Martin NG; Mayordomo JI; Molven A; Mulder S; Nagore E; Novakovic S; Okamoto I; Olafsson JH; Olsson H; Pehamberger H; Peris K; Grasa MP; Planelles D; Puig S; Puig-Butille JA; Randerson-Moor J; Requena C; Rivoltini L; Rodolfo M; Santinami M; Sigurgeirsson B; Snowden H; Song F; Sulem P; Thorisdottir K; Tuominen R; Van Belle P; van der Stoep N; van Rossum MM; Wei Q; Wendt J; Zelenika D; Zhang M; Landi MT; Thorleifsson G; Bishop DT; Amos CI; Hayward NK; Stefansson K; Bishop JAN; Barrett JH
Article: BRITISH JOURNAL OF DERMATOLOGY. 2013;168(4):779-786
Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register
Lyth J; Hansson J; Ingvar C; Mansson-Brahme E; Naredi P; Stierner U; Wagenius G; Lindholm C
Article: GENES CHROMOSOMES AND CANCER. 2013;52(4):378-384
Hereditary uveal melanoma: A report of a germline mutation in BAP1
Hoiom V; Edsgard D; Helgadottir H; Eriksson H; All-Ericsson C; Tuominen R; Ivanova I; Lundeberg J; Emanuelsson O; Hansson J
Article: RHINOLOGY. 2013;51(1):22-30
Primary sinonasal malignant melanoma: a nationwide study of the Swedish population, 1960-2000
Jangard M; Hansson J; Ragnarsson-Olding B
Article: EUROPEAN JOURNAL OF CANCER. 2012;48(13):2012-2019
Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
Brandberg Y; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J
Article: BMC MEDICAL RESEARCH METHODOLOGY. 2012;12:116
Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies
Raimondi S; Gandini S; Fargnoli MC; Bagnardi V; Maisonneuve P; Specchia C; Kumar R; Nagore E; Han J; Hansson J; Kanetsky PA; Ghiorzo P; Gruis NA; Dwyer T; Blizzard L; Fernandez-de-Misa R; Branicki W; Debniak T; Morling N; Landi MT; Palmieri G; Ribas G; Stratigos A; Cornelius L; Motokawa T; Anno S; Helsing P; Wong TH; Autier P; Garcia-Borron JC; Little J; Newton-Bishop J; Sera F; Liu F; Kayser M; Nijsten T
Article: PIGMENT CELL AND MELANOMA RESEARCH. 2012;25(3):384-394
Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study
Davies JR; Randerson-Moor J; Kukalizch K; Harland M; Kumar R; Madhusudan S; Nagore E; Hansson J; Hoiom V; Ghiorzo P; Gruis NA; Kanetsky PA; Wendt J; Pjanova D; Puig S; Saiag P; Schadendorf D; Soufir N; Okamoto I; Affleck P; Garcia-Casado Z; Ogbah Z; Ozola A; Queirolo P; Sucker A; Barrett JH; van Doorn R; Bishop DT; Newton-Bishop J
Article: ACTA ORTHOPAEDICA BELGICA. 2012;78(2):246-253
Surgical treatment of skeletal metastases in 31 melanoma patients
Wedin R; Falkenius J; Weiss RJ; Hansson J
Article: GENES CHROMOSOMES AND CANCER. 2011;50(12):1076-1084
Genome-wide Linkage Analysis of Swedish Families to Identify Putative Susceptibility Loci for Cutaneous Malignant Melanoma
Hoiom V; Tuominen R; Hansson J
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2011;9:204
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gomez H; Bastholt L; Chasalow SD; Berman D
Article: NATURE GENETICS. 2011;43(11):1114-U104
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3
MacGregor S; Montgomery GW; Liu JZ; Zhao ZZ; Henders AK; Stark M; Schmid H; Holland EA; Duffy DL; Zhang M; Painter JN; Nyholt DR; Maskiell JA; Jetann J; Ferguson M; Cust AE; Jenkins MA; Whiteman DC; Olsson H; Puig S; Bianchi-Scarra G; Hansson J; Demenais F; Landi MT; Debniak T; Mackie R; Azizi E; Bressac-de Paillerets B; Goldstein AM; Kanetsky PA; Gruis NA; Elder DE; Newton-Bishop JA; Bishop DT; Iles MM; Helsing P; Amos CI; Wei Q; Wang L-E; Lee JE; Qureshi AA; Kefford RF; Giles GG; Armstrong BK; Aitken JF; Han J; Hopper JL; Trent JM; Brown KM; Martin NG; Mann GJ; Hayward NK
Article: NATURE GENETICS. 2011;43(11):1108-1U98
Genome-wide association study identifies three new melanoma susceptibility loci
Barrett JH; Iles MM; Harland M; Taylor JC; Aitken JF; Andresen PA; Akslen LA; Armstrong BK; Avril M-F; Azizi E; Bakker B; Bergman W; Bianchi-Scarra G; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Corda E; Cust AE; Debniak T; Duffy D; Dunning AM; Easton DF; Friedman E; Galan P; Ghiorzo P; Giles GG; Hansson J; Hocevar M; Hoeiom V; Hopper JL; Ingvar C; Janssen B; Jenkins MA; Joensson G; Kefford RF; Landi G; Landi MT; Lang J; Lubinski J; Mackie R; Malvehy J; Martin NG; Molven A; Montgomery GW; van Nieuwpoort FA; Novakovic S; Olsson H; Pastorino L; Puig S; Puig-Butille JA; Randerson-Moor J; Snowden H; Tuominen R; VanBelle P; van der Stoep N; Whiteman DC; Zelenika D; Han J; Fang S; Lee JE; Wei Q; Lathrop GM; Gillanders EM; Brown KM; Goldstein AM; Kanetsky PA; Mann GJ; MacGregor S; Elder DE; Amos CI; Hayward NK; Gruis NA; Demenais F; Bishop JAN; Bishop DT
Article: CLINICAL CANCER RESEARCH. 2011;17(12):3933-3942
KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites
Omholt K; Grafstrom E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Article: LAKARTIDNINGEN. 2011;108(20):1092-1093
[Paradigmatic shift in oncology: individualized melanoma treatment].
Hansson J; Djureen-Mårtenson E; Edvinsson F; Falkenius J; Friesland S; Masucci G; Månsson-Brahme E; Ragnarsson-Olding B; Sjödin H; Wolodarski M; Frohm-Nilsson M; Lapins J
Article: EXPERIMENTAL CELL RESEARCH. 2011;317(8):1119-1133
Melanoma cells produce multiple laminin isoforms and strongly migrate on α5 laminin(s) via several integrin receptors
Oikawa Y; Hansson J; Sasaki T; Rousselle P; Domogatskaya A; Rodin S; Tryggvason K; Patarroyo M
Article: THE LANCET ONCOLOGY. 2011;12(2):144-152
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(12):2809-2817
High Frequency of p16 ^INK4A Promoter Methylation in NRAS-Mutated Cutaneous Melanoma
Jonsson A; Tuominen R; Grafstrom E; Hansson J; Egyhazi S
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2010;102(20):1568-1583
Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study
Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Bishop JAN; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarra G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Hoiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(8):2062-2070
MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma
Caramuta S; Egyhazi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui W-O
Article: AMERICAN JOURNAL OF HUMAN GENETICS. 2010;87(1):6-16
IRF4 Variants Have Age-Specific Effects on Nevus Count and Predispose to Melanoma
Duffy DL; Iles MM; Glass D; Zhu G; Barrett JH; Hoiom V; Zhao ZZ; Sturm RA; Soranzo N; Hammond C; Kvaskoff M; Whiteman DC; Mangino M; Hansson J; Newton-Bishop JA; Bataille V; Hayward NK; Martin NG; Bishop DT; Spector TD; Montgomery GW
Article: CANCER RESEARCH. 2010;70(11):4335-4345
Immature Immunosuppressive CD14⁺HLA-DR^-/low Cells in Melanoma Patients Are Stat3^hi and Overexpress CD80, CD83, and DC-Sign
Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Article: SCANDINAVIAN JOURNAL OF PLASTIC AND RECONSTRUCTIVE SURGERY AND HAND SURGERY. 2010;44(3):146-155
Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: Results of a prospective randomised trial
Bergenmar M; Mansson-Brahme E; Hansson J; Brandberg Y
Article: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 2010;685:134-145
Familial Cutaneous Melanoma
Hansson J
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2009;58(10):1599-1608
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma
Helgadottir H; Andersson E; Villabona L; Kanter L; van der Zanden H; Haasnoot GW; Seliger B; Bergfeldt K; Hansson J; Ragnarsson-Olding B; Kiessling R; Masucci GV
Article: NATURE GENETICS. 2009;41(8):909-914
New common variants affecting susceptibility to basal cell carcinoma
Stacey SN; Sulem P; Masson G; Gudjonsson SA; Thorleifsson G; Jakobsdottir M; Sigurdsson A; Gudbjartsson DF; Sigurgeirsson B; Benediktsdottir KR; Thorisdottir K; Ragnarsson R; Scherer D; Hemminki K; Rudnai P; Gurzau E; Koppova K; Botella-Estrada R; Soriano V; Juberias P; Saez B; Gilaberte Y; Fuentelsaz V; Corredera C; Grasa M; Hoiom V; Lindblom A; Bonenkamp JJ; van Rossum MM; Aben KKH; de Vries E; Santinami M; Di Mauro MG; Maurichi A; Wendt J; Hochleitner P; Pehamberger H; Gudmundsson J; Magnusdottir DN; Gretarsdottir S; Holm H; Steinthorsdottir V; Frigge ML; Blondal T; Saemundsdottir J; Bjarnason H; Kristjansson K; Bjornsdottir G; Okamoto I; Rivoltini L; Rodolfo M; Kiemeney LA; Hansson J; Nagore E; Mayordomo JI; Kumar R; Karagas MR; Nelson HH; Gulcher JR; Rafnar T; Thorsteinsdottir U; Olafsson JH; Kong A; Stefansson K
Article: NATURE GENETICS. 2009;41(8):920-U85
Genome-wide association study identifies three loci associated with melanoma risk
Bishop DT; Demenais F; Iles MM; Harland M; Taylor JC; Corda E; Randerson-Moor J; Aitken JF; Avril M-F; Azizi E; Bakker B; Bianchi-Scarra G; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Chin-A-Woeng T; Debniak T; Galore-Haskel G; Ghiorzo P; Gut I; Hansson J; Hocevar M; Hoiom V; Hopper JL; Ingvar C; Kanetsky PA; Kefford RF; Landi MT; Lang J; Lubinski J; Mackie R; Malvehy J; Mann GJ; Martin NG; Montgomery GW; van Nieuwpoort FA; Novakovic S; Olsson H; Puig S; Weiss M; van Workum W; Zelenika D; Brown KM; Goldstein AM; Gillanders EM; Boland A; Galan P; Elder DE; Gruis NA; Hayward NK; Lathrop GM; Barrett JH; Bishop JAN
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2009;58(7):1085-1094
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
Johansson CC; Egyhazi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2009;101(12):869-877
Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon
Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Sales F; Patel P; Punt CJA; Hernberg M; Spatz A; ten Hagen TLM; Hansson J; Eggermont AMM
Article: CANCER RESEARCH. 2009;69(9):3746-3754
Species-Specific In vivo Engraftment of the Human BL Melanoma Cell Line Results in an Invasive Dedifferentiated Phenotype Not Present in Xenografts
Cedervall J; Jamil S; Prasmickaite L; Cheng Y; Eskandarpour M; Hansson J; Maelandsmo GM; Ringborg U; Gulyas M; Zhen HS; Kanter L; Ahrlund-Richter L
Article: EUROPEAN JOURNAL OF ONCOLOGY NURSING. 2009;13(2):74-80
Family members' perceptions of genetic testing for malignant melanoma - A prospective interview study
Bergenmar M; Hansson J; Brandberg Y
Article: PIGMENT CELL AND MELANOMA RESEARCH. 2009;22(2):196-204
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
Hoiom V; Tuominen R; Kaller M; Linden D; Ahmadian A; Mansson-Brahme E; Egyhazi S; Sjoberg K; Lundeberg J; Hansson J
Article: NATURE GENETICS. 2009;41(2):221-227
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types
Rafnar T; Sulem P; Stacey SN; Geller F; Gudmundsson J; Sigurdsson A; Jakobsdottir M; Helgadottir H; Thorlacius S; Aben KKH; Bloendal T; Thorgeirsson TE; Thorleifsson G; Kristjansson K; Thorisdottir K; Ragnarsson R; Sigurgeirsson B; Skuladottir H; Gudbjartsson T; Isaksson HJ; Einarsson GV; Benediktsdottir KR; Agnarsson BA; Olafsson K; Salvarsdottir A; Bjarnason H; Asgeirsdottir M; Kristinsson KT; Matthiasdottir S; Sveinsdottir SG; Polidoro S; Hoeiom V; Botella-Estrada R; Hemminki K; Rudnai P; Bishop DT; Campagna M; Kellen E; Zeegers MP; de Verdier P; Ferrer A; Isla D; Vidal MJ; Andres R; Saez B; Juberias P; Banzo J; Navarrete S; Tres A; Kan D; Lindblom A; Gurzau E; Koppova K; de Vegt F; Schalken JA; van der Heijden HFM; Smit HJ; Termeer RA; Oosterwijk E; van Hooij O; Nagore E; Porru S; Steineck G; Hansson J; Buntinx F; Catalona WJ; Matullo G; Vineis P; Kiltie AE; Mayordomo JI; Kumar R; Kiemeney LA; Frigge ML; Jonsson T; Saemundsson H; Barkardottir RB; Jonsson E; Jonsson S; Olafsson JH; Gulcher JR; Masson G; Gudbjartsson DF; Kong A; Thorsteinsdottir U; Stefansson K
Article: INTERNATIONAL JOURNAL OF CANCER. 2009;124(1):16-26
Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro
Eskandarpour M; Huang F; Reeves KA; Clark E; Hansson J
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2008;128(11):2696-2704
Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous Melanoma
Jovanovic B; Kroeckel D; Linden D; Nilsson B; Egyhazi S; Hansson J
Article: MOLECULAR CANCER THERAPEUTICS. 2008;7(9):2876-2883
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Smalley KSM; Lioni M; Palma MD; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Article: NATURE GENETICS. 2008;40(7):886-891
ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma
Gudbjartsson DF; Sulem P; Stacey SN; Goldstein AM; Rafnar T; Sigurgeirsson B; Benediktsdottir KR; Thorisdottir K; Ragnarsson R; Sveinsdottir SG; Magnusson V; Lindblom A; Kostulas K; Botella-Estrada R; Soriano V; Juberias P; Grasa M; Saez B; Andres R; Scherer D; Rudnai P; Gurzau E; Koppova K; Kiemeney LA; Jakobsdottir M; Steinberg S; Helgason A; Gretarsdottir S; Tucker MA; Mayordomo JI; Nagore E; Kumar R; Hansson J; Olafsson JH; Gulcher J; Kong A; Thorsteinsdottir U; Stefansson K
Article: NATURE GENETICS. 2008;40(7):838-840
Common sequence variants on 20q11.22 confer melanoma susceptibility
Brown KM; MacGregor S; Montgomery GW; Craig DW; Zhao ZZ; Iyadurai K; Henders AK; Homer N; Campbell MJ; Stark M; Thomas S; Schmid H; Holland EA; Gillanders EM; Duffy DL; Maskiell JA; Jetann J; Ferguson M; Stephan DA; Cust AE; Whiteman D; Green A; Olsson H; Puig S; Ghiorzo P; Hansson J; Demenais F; Goldstein AM; Gruis NA; Elder DE; Bishop JN; Kefford RF; Giles GG; Armstrong BK; Aitken JF; Hopper JL; Martin NG; Trent JM; Mann GJ; Hayward NK
Article: CANCER RESEARCH. 2007;67(19):9006-9012
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dofou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Article: JOURNAL OF IMMUNOTHERAPY. 2007;30(7):773-779
The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma
Hernberg M; Mattila PS; Rissanen M; Hansson J; Aamdal S; Bastholt L; von der Maase H; Schmidt H; Stierner U; Tarkkanen J
Article: JOURNAL OF MEDICAL GENETICS. 2007;44(2):99-106
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents
Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LAC; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E
Article: MELANOMA RESEARCH. 2006;16(6):471-478
NRAS and BRAF mutations in melanoma turnours in re ation to clinical characteristics:: a study based on mutation screening by pyrosequencing
Edlundh-Rose E; Egyhazi S; Omholt K; Mansson-Brahme E; Platz A; Hansson J; Lundeberg J
Article: CANCER RESEARCH. 2006;66(20):9818-9828
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL
Goldstein AM; Chan M; Harland M; Gillanders EM; Hayward NK; Avril M-F; Azizi E; Bianchi-Scarra G; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cannon Albright LA; Demenais F; Elder DE; Ghiorzo P; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Niendorf K; Newton Bishop J; Palmer JM; Puig S; Puig-Butille JA; de Snoo FA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E
Article: MELANOMA RESEARCH. 2006;16(4):357-363
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma
Masucci GV; Mansson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Article: MELANOMA RESEARCH. 2006;16(2):197-200
Mutations of PIK3CA are rare in cutaneous melanoma
Omholt K; Kröckel D; Ringborg U; Hansson J
Article: CLINICAL CHEMISTRY. 2005;51(12):2388-2391
Detection of MC1R polymorphisms with protease-mediated allele-specific extension as an alternative to direct sequencing
Käller M; Tuominen R; Ahmadian A; Magnusson V; Egyhazi S; Hansson J; Lundeberg J
Article: SKIN RESEARCH AND TECHNOLOGY. 2005;11(4):281-286
Non-invasive and microinvasive electrical impedance spectra of skin cancer -: a comparison between two techniques
Åberg P; Geladi P; Nicander I; Hansson J; Holmgren U; Ollmar S
Article: INTERNATIONAL JOURNAL OF CANCER. 2005;115(1):65-73
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
Eskandarpour M; Kiaii S; Zhu CY; Castro J; Sakko AJ; Hansson J
Article: CLINICAL CANCER RESEARCH. 2005;11(8):2991-2997
Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival
Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
Article: MELANOMA RESEARCH. 2005;15(2):125-132
Effect of primary site on prognosis in patients with cutaneous malignant melanoma.: A study using a new model to analyse anatomical locations
Gillgren P; Brattström G; Frisell J; Persson JO; Ringborg U; Hansson J
Article: IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING. 2004;51(12):2097-2102
Skin cancer identification using multifrequency electrical impedance -: A potential screening tool
Åberg P; Nicander I; Hansson J; Geladi P; Holmgren U; Ollmar S
Article: CANCER. 2004;101(9):2067-2078
Invasive cutaneous malignant melanoma in Sweden, 1990-1999 -: A prospective, population-based study of survival and prognostic factors
Lindholm C; Andersson R; Dufmats M; Hansson J; Ingvar C; Möller T; Sjödin H; Stierner U
Article: THE LARYNGOSCOPE. 2004;114(9):1660-1667
High-dose cisplatin with amifostine: Ototoxicity and pharmacokinetics
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Article: MELANOMA RESEARCH. 2004;14(4):251-255
Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma
Berg P; Wennberg AM; Tuominen R; Sander B; Rozell BL; Platz A; Hansson J
Article: CANCER RESEARCH. 2004;64(3):807-811
Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B
Berking C; Takemoto R; Satyamoorthy K; Shirakawa T; Eskandarpour M; Hansson J; VanBelle PA; Elder DE; Herlyn M
Article: ACTA ONCOLOGICA. 2004;43(2):161-168
Anxiety and depressive symptoms measured by the hospital anxiety and depression scale as predictors of time to recurrence in localized cutaneous melanoma
Bergenmar M; Nilsson B; Hansson J; Brandberg Y
Article: HUMAN PATHOLOGY. 2004;35(1):25-33
Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients
Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
Article: CLINICAL CANCER RESEARCH. 2003;9(17):6483-6488
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Article: BRITISH JOURNAL OF CANCER. 2003;89(8):1517-1523
O⁶-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma
Ma S; Egyházi S; Ueno T; Lindholm C; Kreklau EL; Stierner U; Ringborg U; Hansson J
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2003;95(20):1530-1538
A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women
Veierod MB; Weiderpass E; Thörn M; Hansson J; Lund E; Armstrong B; Adami HO
Article: AMERICAN JOURNAL OF HUMAN GENETICS. 2003;73(2):301-313
Localization of a novel melanoma susceptibility locus to 1p22
Gillanders E; Juo SHH; Holland EA; Jones M; Nancarrow D; Freas-Lutz D; Sood R; Park N; Faruque M; Markey C; Kefford RF; Palmer J; Bergman W; Bishop DT; Tucker MA; Bressac-de Paillerets B; Hansson J; Stark M; Gruis N; Bishop JN; Goldstein AM; Bailey-Wilson JE; Mann GJ; Hayward N; Trent J
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2003;95(11):790-798
Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
Article: MELANOMA RESEARCH. 2003;13(3):279-286
Body site of cutaneous malignant melanoma -: a study on patients with hereditary and multiple sporadic tumours
Gillgren P; Brattström G; Frisell J; Palmgren J; Ringborg U; Hansson J
Article: EUROPEAN JOURNAL OF CANCER. 2003;39(8):1115-1120
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma
Kivelä T; Suciu S; Hansson J; Kruit WHJ; Vuoristo MS; Kloke O; Gore M; Hahka-Kemppinen M; Parvinen LM; Kumpulainen E; Humblet Y; Pyrhönen S
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2003;278(11):9100-9106
Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling
Mandic A; Hansson J; Linder S; Shoshan MC
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2003;37(2):106-111
Bladder neoplasms -: Regions at chromosome 9 with putative tumour suppressor genes
Wada T; Berggren P; Steineck G; Adolfsson J; Wijkström H; Norming U; Hansson J; Hernminkil K; Larsson P
Article: CLINICAL CHEMISTRY. 2002;48(12):2164-2170
Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases
Sivertsson Å; Platz A; Hansson J; Lundeberg J
Article: HUMAN MUTATION. 2002;20(5):408-409
Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden.
Egyházi S; Ma S; Smoczynski K; Hansson J; Platz A; Ringborg U
Article: CLINICAL CANCER RESEARCH. 2002;8(11):3468-3474
Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas:: Mutations occur early and persist throughout tumor progression
Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
Article: ONCOLOGY REPORTS. 2002;9(5):1015-1019
Immunohistochemical analysis of DNA mismatch repair protein and O⁶-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy
Ma S; Egyházi S; Ringborg U; Hansson J
Article: MELANOMA RESEARCH. 2002;12(4):335-342
Analysis of O⁶-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy
Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
Article: CANCER LETTERS. 2002;180(2):211-221
A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF
Hashemi J; Lindström MS; Asker C; Platz A; Hansson J; Wiman KG
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2002;94(12):894-903
Geographical variation in the penetrance of CDKN2A mutations for melanoma
Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA
Article: BRITISH JOURNAL OF DERMATOLOGY. 2002;146(6):1023-1030
A new computerized methodology to analyse tumour site in relation to phenotypic traits and epidemiological characteristics of cutaneous malignant melanoma
Gillgren P; Brattström G; Mårtensson ED; Frisell J; Palmgren J; Ringborg U; Hansson J
Article: MOLECULAR AND CELLULAR BIOLOGY. 2002;22(9):3003-3013
Calpain-mediated bid cleavage and calpain-independent Bak modulation: Two separate pathways in cisplatin-induced apoptosis
Mandic A; Viktorsson K; Strandberg L; Heiden T; Hansson J; Linder S; Shoshan MC
Article: CYTOPATHOLOGY. 2002;13(1):11-21
Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma
Sviatoha V; Rundgren Å; Tani E; Hansson J; Kleina R; Skoog L
Article: EUROPEAN JOURNAL OF CANCER PREVENTION. 2002;11(1):49-55
Detection of nodular and superficial spreading melanoma with tumour thickness ≤2.0 mm -: An interview study
Bergenmar M; Hansson J; Brandberg Y
Article: INTERNATIONAL JOURNAL OF CANCER. 2001;92(6):839-842
Cytoplasmic and nuclear accumulation of β-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma
Omholt K; Platz A; Ringborg U; Hansson J
Article: BJU INTERNATIONAL. 2001;87(9):876-881
The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction
Wada T; Louhelainen J; Hemminki K; Adolfsson J; Wijkström H; Norming U; Borgström E; Hansson J; Steineck G
Article: BRITISH JOURNAL OF CANCER. 2001;84(11):1505-1511
p53 mutations in urinary bladder cancer
Berggren P; Steineck G; Adolfsson J; Hansson J; Jansson O; Larsson P; Sandstedt B; Wijkström H; Hemminki K
Article: MOLECULAR AND CELLULAR BIOLOGY. 2001;21(11):3684-3691
Cisplatin induces the proapoptotic conformation of Bak in a ΔMEKK1-dependent manner
Mandic A; Viktorsson K; Molin M; Akusjärvi G; Eguchi H; Hayashi SI; Toi M; Hansson J; Linder S; Shoshan MC
Article: GENES CHROMOSOMES AND CANCER. 2001;31(2):107-116
Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families
Hashemi J; Bendahl PO; Sandberg T; Platz A; Linder S; Stierner U; Olsson H; Ingvar C; Hansson J; Borg A
Article: BRITISH JOURNAL OF CANCER. 2001;84(3):329-334
Low interleukin-1α messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma
Seddighzadeh M; Steineck G; Jansson O; Larsson P; Wijkström H; Adolfsson J; Portwood N; Hansson J; Linder S
Article: MELANOMA RESEARCH. 2001;11(1):11-19
The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis
Mandic A; Viktorsson K; Heiden T; Hansson J; Shoshan MC
Article: JOURNAL OF CLINICAL ONCOLOGY. 2001;19(3):824-831
Serum S-100B protein as a prognostic marker in malignant cutaneous melanoma
Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Brahme EM; Ringborg U; Hansson J
Article: CANCER RESEARCH. 2000;60(24):6864-6867
CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Article: SEMINARS IN CANCER BIOLOGY. 2000;10(4):319-326
Hereditary cutaneous melanoma
Platz A; Ringborg U; Hansson J
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2000;92(9):758A-7759
Re:: Biologic and biochemical analyses of p16^INK4a mutations from primary tumors
Hansson J; Hashemi J; Linder S; Platz A
Article: CLINICAL CANCER RESEARCH. 2000;6(2):610-615
Bladder cancer:: Allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade
Wada T; Louhelainen J; Hemminki K; Adolfsson J; Wijkström H; Norming U; Borgström E; Hansson J; Sandstedt B; Steineck G
Article: MELANOMA RESEARCH. 1999;9(1):21-30
Melanoma development in relation to nonfunctional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds
Hashemi J; Linder S; Platz A; Hansson J
Article: INTERNATIONAL JOURNAL OF CANCER. 1998;78(1):13-15
Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma:: A clinic-based population study
Platz A; Hansson J; Ringborg U
Article: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 1998;18(9):691-695
In vivo induction of the interferon-stimulated protein 2′5′ oligoadenylate synthetase in tumor and peripheral blood cells during IFN-α treatment of metastatic melanoma
Grandér D; Sangfelt O; Skoog L; Hansson J
Article: CARCINOGENESIS. 1997;18(10):1889-1895
O-6-methylguanine-DNA methyltransferase activity in human buccal mucosal tissue and cell cultures. Complex mixtures related to habitual use of tobacco and betel quid inhibit the activity in vitro
Liu Y; Egyhazi S; Hansson J; Bhide SV; Kulkarni PS; Grafstrom RC
Article: LAKARTIDNINGEN. 1997;94(28-29):2543-2544
[Delayed diagnosis of subungual melanoma. Two cases were misjudged as onychomycosis].
Wallberg B; Hansson J
Article: LAKARTIDNINGEN. 1997;94(28-29):2539-2543
[Malignant skin melanoma a difficult clinical diagnosis. The primary management is often insufficient].
Wallberg B; Hansson J
Article: ANTICANCER RESEARCH. 1997;17(4B):3071-3073
Prognostic value of serum analyses of S-100 protein beta in malignant melanoma
Hansson LO; VonSchoultz E; Djureen E; Hansson J; Nilsson B; Ringborg U
Article: ANTICANCER RESEARCH. 1997;17(4A):2347-2352
The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line
Fokstuen T; Rabo YB; Zhou JN; Karlson J; Platz A; Shoshan MC; Hansson J; Linder S
Article: MEDICAL ONCOLOGY. 1997;14(2):73-81
Systemic therapy of malignant melanoma
Hansson J
Article: STEM CELLS AND DEVELOPMENT. 1997;6(3):253-260
Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis)
Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1997;89(10):697-702
Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma
Platz A; Hansson J; ManssonBrahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganas M; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(3):447-452
Role of O-6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line
Egyhazi S; Edgren MR; Hansson J; Krockel D; Mannervik B; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(1):129-134
Immunohistochemical examination of the expression of O-6-methylguanine-DNA methyltransferase in human melanoma metastases
Egyhazi S; Margison GP; Hansson J; Ringborg U
Article: CARCINOGENESIS. 1997;18(1):9-13
Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients
Hemminki K; Rajaniemi H; Koskinen M; Hansson J
Article: EUROPEAN JOURNAL OF CANCER. 1996;32A(13):2319-2326
Analysis of O-6 methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction
Hansson J; Martenhed G; Egyhazi S; Tani E; Platz A
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1996;26(6):1308-1313
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity
Kono K; SalazarOnfray F; Petersson M; Hansson J; Masucci G; Wasserman K; Nakazawa T; Anderson P; Kiessling R
Article: MELANOMA RESEARCH. 1996;6(2):133-137
Prognostic value of serum analyses of S-100 beta protein in malignant melanoma
vonSchoultz E; Hansson LO; Djureen E; Hansson J; Karnell A; Nilsson B; Stigbrand T; Ringborg U
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;65(6):821-826
Different mechanisms are responsible for c-jun mRNA induction by cisplatin and ultraviolet light
Rabo YB; Shoshan MC; Linder S; Hansson J
Article: ACTA ONCOLOGICA. 1996;35(6):683-690
Increased cisplatin sensitivity of human fibroblasts from a subject with inherent glutathione deficiency
Hansson J; Edgren MR; Egyhazi S; Hao XY; Mannervik B; Ringborg U
Article: ANTI-CANCER DRUGS. 1995;6(5):657-668
APOPTOSIS AND C-JUN INDUCTION BY CISPLATIN IN A HUMAN-MELANOMA CELL-LINE AND A DRUG-RESISTANT DAUGHTER CELL-LINE
ZHAO R; RABO YB; EGYHAZI S; ANDERSSON A; EDGREN MR; LINDER S; HANSSON J
Article: ACTA ONCOLOGICA. 1995;34(1):35-41
THE EXPRESSION OF GLUTATHIONE TRANSFERASE ISOENZYMES IN HUMAN-MALIGNANT LYMPHOMA BIOPSIES
BERHANE K; HAO XY; CHRISTENSSON B; HANSSON J; RINGBORG U; MANNERVIK B
Show more

All other publications

Editorial comment: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2022;142(3 PT A):736-740.e6
Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma
Das I; Tuominen R; Helleday T; Hansson J; Berglund UW; Brage SE
Editorial comment: ACTA DERMATO-VENEREOLOGICA. 2020;100(18):adv00334-0
Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma
Eriksson H; Hansson J; Krynitz B; Masucci G; Girnita A; Lapins J; Huen AO; Tawbi HA; Davies MA; Tetzlaff MT; Curry JL
Corrigendum: ANNALS OF ONCOLOGY. 2019;30(11):1848
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (vol 28, pg 1631, 2017)
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandala M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob J-J
Corrigendum: NATURE COMMUNICATIONS. 2019;10(1):299
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways (vol 9, 4774, 2018)
Duffy DL; Zhu G; Li X; Sanna M; Iles MM; Jacobs LC; Evans DM; Yazar S; Beesley J; Law MH; Kraft P; Visconti A; Taylor JC; Liu F; Wright MJ; Henders AK; Bowdler L; Glass D; Ikram MA; Uitterlinden AG; Madden PA; Heath AC; Nelson EC; Green AC; Chanock S; Barrett JH; Brown MA; Hayward NK; MacGregor S; Sturm RA; Hewitt AW; Kayser M; Hunter DJ; Bishop JAN; Spector TD; Montgomery GW; Mackey DA; Smith GD; Nijsten TE; Bishop DT; Bataille V; Falchi M; Han J; Martin NG; Lee JE; Brossard M; Moses EK; Song F; Kumar R; Easton DF; Pharoah PDP; Swerdlow AJ; Kypreou KP; Harland M; Randerson-Moor J; Akslen LA; Andresen PA; Avril M-F; Azizi E; Scarra GB; Brown KM; Debniak T; Elder DE; Fang S; Friedman E; Galan P; Ghiorzo P; Gillanders EM; Goldstein AM; Gruis NA; Hansson J; Helsing P; Hocevar M; Hoiom V; Ingvar C; Kanetsky PA; Chen WV; Landi MT; Lang J; Lathrop GM; Lubinski J; Mackie RM; Mann GJ; Molven A; Novakovic S; Olsson H; Puig S; Puig-Butille JA; Radford-Smith GL; van der Stoep N; van Doorn R; Whiteman DC; Craig JE; Schadendorf D; Simms LA; Burdon KP; Nyholt DR; Pooley KA; Orr N; Stratigos AJ; Cust AE; Ward SV; Schulze H-J; Dunning AM; Demenais F; Amos CI
Letter: EUROPEAN JOURNAL OF CANCER. 2018;91:168-170
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III
Grob JJ; Schadendorf D; Lorigan P; Ascierto P; Larkin J; Nathan P; Robert C; Hauschild A; Weber J; Daud A; Hamid O; Dummer R; Hansson J; Hoeller C; Schachter J; Van Akkooi ACJ; Garbe C
Letter: ANNALS OF ONCOLOGY. 2017;28(7):1672-1673
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma
Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
Review: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2017;31(4):603-615
Surgical outcomes in patients with cutaneous malignant melanoma in Europe - a systematic literature review
Svedman FC; Spanopoulos D; Taylor A; Amelio J; Hansson J
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2016;136(5):1066-1069
Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families
Taylor NJ; Handorf EA; Mitra N; Avril M-F; Azizi E; Bergman W; Bianchi-Scarra G; Bishop DT; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Friedman E; Gerdes A-M; Ghiorzo P; Goldstein AM; Grazziotin TC; Hansson J; Hayward NK; Hocevar M; Hoiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer J; Peric B; Pjanova D; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Whitaker L; Yang XR; Bishop JAN; Gruis NA; Kanetsky PA
Review: CLINICAL EPIDEMIOLOGY. 2016;8:109-122
Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature
Svedman FC; Pillas D; Taylor A; Kaur M; Linder R; Hansson J
Corrigendum: TRIALS. 2015;16:334
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial (vol 15, 317, 2014)
Bagge RO; Ny L; All-Ericsson C; Eilard MS; Rizell M; Cahlin C; Stierner U; Lonn U; Hansson J; Ljuslinder I; Lundgren L; Ullenhag G; Kiilgaard JF; Nilsson J; Lindner P
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2014;134(12):3000-3003
Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass
Staaf J; Harbst K; Lauss M; Ringner M; Masback A; Howlin J; Jirstrom K; Harland M; Zebary A; Palmer JM; Ingvar C; Olsson H; Newton-Bishop J; Hansson J; Hayward N; Gruis N; Jonsson G
Review: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2014;63(9):977-983
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
de Coana YP; Masucci G; Hansson J; Kiessling R
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2014;134(1):287-290
Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study
Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Johansson CH; Hoiom V; Jonsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Brage SE; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J
Corrigendum: CANCER IMMUNOLOGY RESEARCH. 2013;1(6):438
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid Derived Suppressor Cells as well as Their Arginase1 Production (vol 1, pg 158, 2013)
de Coana YP; Poschke I; Gentilcore G; Mao Y; Nystrom M; Hansson J; Masucci GV; Kiessling R
Review: LAKARTIDNINGEN. 2013;110(17-18):886-888
[Hedgehog inhibitors. New promising treatment of advanced basal cell carcinoma].
Wolodarski M; Lapins J; Hansson J
Review: LAKARTIDNINGEN. 2013;110(8):410-412
[Synchronous multiple primary melanoma are often missed. Increased attention to the patient's entire skin is required for early diagnosis].
Lapins J; Emtestam L; Hedblad M-A; Girnita A; Lindelöf B; Ljung A; Hansson J
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2013;85(2):149-161
Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review
Ascierto PA; Gogas HJ; Grob JJ; Martin Algarra S; Mohr P; Hansson J; Hauschild A
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(2):618-620
Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations
Jovanovic B; Egyhazi S; Eskandarpour M; Ghiorzo P; Palmer JM; Scarra GB; Hayward NK; Hansson J
Meeting abstract: EJC SUPPLEMENTS. 2009;7(2):577
Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma
Schmidt H; Hamid O; Nissan A; Guida M; Aamdal S; Hansson J; Ridolfi R; Berman D; Chasalow SD
Corrigendum: NATURE GENETICS. 2008;40(8):1029
ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma (vol 40, pg 886, 2008)
Gudbjartsson DF; Sulem P; Stacey SN; Goldstein AM; Rafnar T; Sigurgeirsson B; Benediktsdottir KR; Thorisdottir K; Ragnarsson R; Sveinsdottir SG; Magnusson V; Lindblom A; Kostulas K; Botella-Estrada R; Soriano V; Juberias P; Grasa M; Saez B; Andres R; Scherer D; Rudnai P; Gurzau E; Koppova K; Kiemeney LA; Jakobsdottir M; Steinberg S; Helgason A; Gretarsdottir S; Tucker MA; Mayordomo JI; Nagore E; Kumar R; Hansson J; Olafsson JH; Gulcher J; Kong A; Thorsteinsdottir U; Stefansson K
Other: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2008;128(8):1875-1877
Meeting report of the conference on UV-Radiation-Induced Disease--Roles of UVA and UVB.
Emeny J; Hansson J; Toftgård R; Segerbäck D
Review: SURGICAL CLINICS OF NORTH AMERICA. 2008;88(4):897-viii
Familial melanoma
Hansson J
Review: MOLECULAR ONCOLOGY. 2008;1(4):395-405
Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
Platz A; Egyhazi S; Ringborg W; Hansson J
Corrigendum: CANCER RESEARCH. 2008;68(4):1245
The FBXW7 gene is mutated in a variety of human tumors (vol 67, pg 9006, 2007)
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Capeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Letter: MELANOMA RESEARCH. 2007;17(6):410-412
No evidence of RALGDS mutations in cutaneous melanoma
Omholt K; Hansson J
Meeting abstract: EJC SUPPLEMENTS. 2007;5(4):40
Managing melanoma families in the clinic
Hansson J
Meeting abstract: EJC SUPPLEMENTS. 2007;5(6):4
Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma
Hansson J; Aamdal S; Bastholt L; Hernberg M; Nilsson B; Stierner U; von der Maase H
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(19):2819-2824
Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome:: Results of a Swedish preventive program
Hansson J; Bergenmar M; Hofer P-A; Lundell G; Mansson-Brahme E; Ringborg U; Synnerstad I; Bratel AT; Wennberg A-M; Rosdahl I
Editorial comment: ACTA ONCOLOGICA. 2006;45(4):369-372
Adjuvant therapy of cutaneous melanoma - current status
Hansson J
Editorial comment: ACTA ONCOLOGICA. 2005;44(7):773-777
Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex®)
Ragnarsson-Olding B; Djureen-Mårtensson E; Månsson-Brahme E; Hansson J
Editorial comment: THE LANCET ONCOLOGY. 2002;3(11):653-654
Genetic testing for melanoma.
Kefford R; Bishop JN; Tucker M; Bressac-de Paillerets B; Bianchi-Scarrá G; Bergman W; Goldstein A; Puig S; Mackie R; Elder D; Hansson J; Hayward N; Hogg D; Olsson H; Melanoma Genetics Consortium
Letter: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2000;92(9):758-760
Re: biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Hansson J; Hashemi J; Linder S; Platz A
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1999;35:S369
CDKN2A germline mutations in Swedish kindreds with hereditary cutaneous melanomas
Hansson J; Platz A; Hashemi J; Stierner U; Ringborg U
Editorial comment: ACTA ONCOLOGICA. 1998;37(7-8):627-628
Why some tumors fail to respond to chemotherapy - Comments on a new model of drug sensitivity and resistance
Hansson J
Published conference paper: DRUGS OF TODAY. 1996;32:51-59
Modulating nitrosourea response in tumors and normal tissue: Application to fotemustine
Margison GP; Rafferty JA; Elder RH; Kelly J; Watson AJ; Willington MA; Lee SM; Hickson I; Fairbairn LJ; Dexter TM; Jelinek J; Stocking C; Baum C; Ostertag W; Eghyazi S; Hansson J; Ringborg U; Donnelly D; McMurry TBH; McCormick J; McElhinney RS
Other: BRITISH JOURNAL OF CANCER. 1995;71(1):37-39
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITIES IN BIOPSIES OF HUMAN-MELANOMA TUMORS
EGYHAZI S; HANSSON J; RINGBORG U
Show more

Employments

Professor Emeritus/Emerita, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, Karolinska Institutet, 1992

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI